Discover BioCryst's strong Q1 2025 performance with ORLADEYO revenue up 33%-37%, early profitability, pipeline growth & bold forecasts.

In the first quarter, BioCryst swung to a profit of $32,000, or less than a penny a share from a loss of $35.4 million, or 17 cents a share, a year earlier. Revenue surged 57% to $145.5 million, ...

RESEARCH TRIANGLE PARK, N.C., May 05, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today reported ...

ORLADEYO net revenue of $134.2 million (+51 percent y-o-y)- -Full year 2025 ORLADEYO revenue guidance increased to $580 million to $600 million- -Company now expects to be profitable for full ...